Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Endovascular Therapy for Post-Thrombotic Syndrome - A Randomized Trial.
Journal: The New England journal of medicine
Published: April 13, 2026
Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results.
Journal: Research and practice in thrombosis and haemostasis
Published: October 02, 2025
Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial.
Journal: Research and practice in thrombosis and haemostasis
Published: August 01, 2024
Pegcetacoplan in paroxysmal nocturnal haemoglobinuria: Its use, its clinical effectiveness, and its influence on health-related quality of life and productivity.
Journal: European journal of haematology
Published: September 29, 2023
Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1.
Journal: Journal of thrombosis and haemostasis : JTH
Published: December 13, 2022
Valoctocogene roxaparvovec gene transfer in participants with HIV.
Journal: Blood advances
Published: October 24, 2022
NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease.
Journal: PloS one
Published: October 13, 2016
Peters plus syndrome mutations disrupt a noncanonical ER quality-control mechanism.
Journal: Current biology : CB
Published: September 12, 2014
Sickle cell disease (SCD), iNKT cells, and regadenoson infusion.
Journal: Transactions of the American Clinical and Climatological Association
Published: January 11, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026